Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 313

Sort by

Sort Order Select

Journal Articles

Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials

Blood blood.2025030741.

https://doi.org/10.1182/blood.2025030741

Published: 2025

Includes: Supplemental data

Journal Articles

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia

Marlise R. Luskin, Mark A. Murakami, Julia Keating, Yael Flamand, Eric S. Winer, Jacqueline S. Garcia, Maximilian Stahl, Richard M. Stone, Martha Wadleigh, Stella L. Jaeckle, Ella Hagopian, David M. Weinstock, Jessica Liegel, Malgorzata McMasters, Eunice S. Wang, Wendy Stock, Daniel J. DeAngelo

Blood (2025) 145 (6): 577–589.

https://doi.org/10.1182/blood.2024025800

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Josh Zhang, Shai O. Shimony, Yiwen Liu, Eno Inyang, Evan C. Chen, Luis E. Aguirre, Rebecca P. Bystrom, Benjamin Rolles, Richard M. Stone, Daniel J. DeAngelo, Emily Tiao, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 5175.

https://doi.org/10.1182/blood-2024-200358

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

Shai O. Shimony, Yating Wang, Angel Cronin, Thomas P Walsh, Anne Charles, Natalie Slopen, Maximilian Stahl, Rebecca P. Bystrom, Marlise R. Luskin, Gregory Abel, Daniel J. DeAngelo, Richard M Stone, R. Coleman Lindsley, Andrew Hantel

Blood (2024) 144 (Supplement 1): 5171.

https://doi.org/10.1182/blood-2024-203644

Published: 2024

Journal Articles

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood (2024) 144 (Supplement 1): 659.

https://doi.org/10.1182/blood-2024-193678

Published: 2024

Journal Articles

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Blood (2024) 144 (Supplement 1): 4267.

https://doi.org/10.1182/blood-2024-202744

Published: 2024

Journal Articles

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Claire Roddie, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin A Pule, Justin Shang, Elias Jabbour

Blood (2024) 144 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2024-208028

Published: 2024

Journal Articles

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Bijal D Shah, Jeremy Pantin, Karamjeet S Sandhu, Elias Jabbour, Jae H. Park, Paul Shaughnessy, Mehrdad Abedi, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin Brown, Dilip Patel, Claire Roddie, Aaron C. Logan

Blood (2024) 144 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2024-205694

Published: 2024

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Response in Patients with Chronic Myelogenous Leukemia (CML) and BCR-ABL 35 Base Pair Intron 8 Insertion (35INS)

Roxana A Portillo, Michelle Hyunju Lee, Harrison K. Tsai, Daniel J DeAngelo, Amir T. Fathi, Rupa Narayan, Marlise R Luskin, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6598.

https://doi.org/10.1182/blood-2024-206655

Published: 2024

Journal Articles

Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

Chi-Joan How, Yiwen Liu, Kathleen Gallagher, Emma K Logan, Ann Mullally, Donna S. Neuberg, Thomas Reardon, Alyssa Watson, Daniel J. DeAngelo, Rushad Patell, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6644.

https://doi.org/10.1182/blood-2024-194126

Published: 2024

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Jae H. Park, Elias Jabbour, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Justin Shang, Claire Roddie

Blood (2024) 144 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2024-201514

Published: 2024

Journal Articles

Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting

Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H. Radia, Johannes Luebke, Priyanka J. Bobbili, Aolin Wang, Saša Dimitrijević, Erin Sullivan, Juliana Schwaab, Ilene A. Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Manasi Mohan, Teshawna Badu, Mei Sheng Duh, Peter Valent, Daniel J. DeAngelo

Blood (2024) 144 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2024-204015

Published: 2024

Journal Articles

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 1): 308.

https://doi.org/10.1182/blood-2024-209438

Published: 2024

Journal Articles

Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Blood (2024) 144 (Supplement 1): 779.

https://doi.org/10.1182/blood-2024-207557

Published: 2024

Journal Articles

Frailty and Long-Term Survival Among Older Adults with Blood Cancers

Clark DuMontier, Angel Cronin, Tammy T Hshieh, Ameya Sanyal, Michelle Fredericks, Nicholas Groblewski, Lee Mozessohn, Daniel J DeAngelo, Richard M Stone, Robert J. Soiffer, Jane A Driver, Gregory A Abel

Blood (2024) 144 (Supplement 1): 448.

https://doi.org/10.1182/blood-2024-203896

Published: 2024

Journal Articles

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Blood (2024) 144 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2024-209087

Published: 2024

Journal Articles

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4569.1.

https://doi.org/10.1182/blood-2024-194550

Published: 2024

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit Rampal, Daniel J DeAngelo, Virginia O. Volpe, Kristen M. Pettit, Gerard Hoehn, Sasa Dimitrijevic, Rami S. Komrokji, Eric Padron

Blood (2024) 144 (Supplement 1): 4569.2.

https://doi.org/10.1182/blood-2024-211148

Published: 2024

Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood (2024) 144 (Supplement 1): 733.

https://doi.org/10.1182/blood-2024-209097

Published: 2024

Journal Articles

Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Daniel J. DeAngelo, Ying Chen, Ryan D. Cassaday, Jennifer Hibma, Derek Z Yang, May Garrett, Fan Zhang, Svetoslav H Dimitrov, Erik Vandendries, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 732.

https://doi.org/10.1182/blood-2024-194244

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia

Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Tyrosine Kinase Inhibitor (TKI) Response in Patients with Chronic Myelogenous Leukemia (CML) and BCR-ABL 35 Base Pair Intron 8 Insertion (35INS)

Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Frailty and Long-Term Survival Among Older Adults with Blood Cancers

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only